Autonomix Medical, Inc. (AMIX) AI Stock Analysis

• Market Cap: $4.33M
• Dividend Yield: N/A
• Average Volume (3M): 240.70K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.42
• Revenue Growth: N/A
• EPS Growth: -10.29%
• Country: US
• Employees: 5
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Devices
• EPS (TTM): -12.53
• Shares Outstanding: 2,462,983
• 10 Day Avg. Volume: 417,185
• 30 Day Avg. Volume: 240,703
• PEG Ratio: <0.01
• Price to Book (P/B): 0.34
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.54
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.00
• Price Target Upside: 177.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: ―

Autonomix Medical, Inc. struggles with severe financial performance issues due to zero revenue and negative cash flow, despite low debt levels. Technical analysis suggests some short-term momentum, but a longer-term downtrend persists. Valuation is significantly impacted by negative earnings and no dividend yield. Positive trial outcomes present a potential opportunity but are insufficient to offset the substantial financial challenges.

Positive Factors

Clinical Trials

Positive topline data from initial proof of concept human trial in pancreatic cancer pain indicates the effectiveness of AMIX's technology.

Market Opportunity

The follow-on PoC trial has the potential to expand the addressable market beyond pancreatic cancer pain by evaluating additional visceral cancers.

Technology Advancement

AMIX's catheter-based sensing technology is 3,000 times more sensitive than alternative methods, enhancing precision in nerve ablation procedures.

Negative Factors

Financial Strategy

AMIX is prioritizing pancreatic cancer pain due to the significant unmet need, which could indicate a narrow focus that may limit broader market opportunities.

Market Competition

The company's focus on pancreatic cancer pain management faces the challenge of competing against established treatments and therapies.

Autonomix Medical, Inc. Business Overview & Revenue Model

Company Description

Autonomix Medical, Inc., a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.

How the Company Makes Money

Autonomix Medical, Inc. generates revenue through the sale of its medical devices and software solutions to hospitals, clinics, and healthcare professionals. Key revenue streams include one-time sales of its proprietary hardware, subscription-based licensing for its software platforms, and service agreements for ongoing maintenance and support. The company also engages in strategic partnerships with healthcare providers and technology firms to expand its reach and enhance its product offerings. Additionally, AMIX may earn revenue from research and development collaborations and intellectual property licensing agreements.

Autonomix Medical, Inc. Financial Statement Overview

Summary

Autonomix Medical, Inc. is facing significant challenges with zero revenue and negative cash flows, despite low debt levels. The company's reliance on financing for operations poses substantial risks.

Income Statement

Autonomix Medical, Inc. is facing significant challenges with its income statement. The company reports zero total revenue across all periods, leading to negative gross profit, EBIT, and net income. The lack of revenue generation reflects a critical concern for the company's growth prospects and profitability.

Balance Sheet

The balance sheet shows a reasonable equity position with a debt-to-equity ratio indicating low leverage, which is positive. However, the equity ratio has declined over the periods, suggesting an increase in liabilities relative to assets. The company appears to maintain a low level of debt, which mitigates risk, but there is little improvement in asset growth.

Cash Flow

Cash flow analysis reveals negative free cash flow and operating cash flow, indicative of operational challenges. The company is heavily reliant on financing activities to sustain operations, which could pose risks if external funding becomes less accessible. Although capital expenditure is minimal, the negative free cash flow suggests a need for strategic adjustments.

Breakdown
TTM	Mar 2024	Mar 2023	Mar 2022
Income Statement		Total Revenue
0.00	0.00	0.00	0.00
	Gross Profit
-89.00K	-81.00K	0.00	0.00
	EBIT
-10.75M	-7.47M	-1.99M	-13.59M
	EBITDA
-13.27M	-15.27M	0.00	752.45K
	Net Income Common Stockholders
-13.63M	-15.43M	-1.99M	-13.33M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
11.82M	8.61M	864.62K	2.04M
	Total Assets
11.95M	9.41M	864.62K	2.05M
	Total Debt
1.13M	1.00M	0.00	0.00
	Net Debt
-10.69M	-7.61M	-864.62K	-2.04M
	Total Liabilities
2.25M	1.78M	220.59K	93.24K
	Stockholders Equity
9.71M	7.63M	644.03K	1.96M
Cash Flow		Free Cash Flow
-8.06M	-6.67M	-1.85M	-387.31K
	Operating Cash Flow
-8.04M	-6.65M	-1.85M	-387.31K
	Investing Cash Flow
-29.00K	-19.00K	0.00	0.00
	Financing Cash Flow
18.65M	14.41M	675.00K	2.43M

Autonomix Medical, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMIX, the sentiment is Negative. The current price of 1.8 is below the 20-day moving average (MA) of 1.96, below the 50-day MA of 1.88, and below the 200-day MA of 6.49, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 47.29 is Neutral, neither overbought nor oversold. The STOCH value of 48.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMIX.

Autonomix Medical, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	$4.84B	20.17	-16.90%	5.21%	13.60%	-28.06%
NUWE	49 Neutral	$4.01M	―	-440.77%	―	-1.21%	93.72%
HSCS	46 Neutral	$4.28M	―	-163.47%	―	-100.00%	78.91%
SINT	42 Neutral	$7.05M	―	-155.20%	―	9.90%	94.56%
AMIX	40 Underperform	$4.33M	―	-662.74%	―	―	-10.29%
RSLS	37 Underperform	$3.51M	―	-120.16%	―	-7.74%	93.25%

Autonomix Medical, Inc. Corporate Events

Autonomix Medical Announces Positive Trial Outcomes

On April 30, 2025, Autonomix Medical, Inc. announced positive outcomes from the initial phase of its first-in-human proof-of-concept trial for treating severe pancreatic cancer pain. The trial demonstrated significant pain reduction and improved quality of life, with 100% of patients achieving zero opioid use at 7 days post-procedure. Following these results, the company plans to expand its study to include additional visceral cancers and earlier-stage pancreatic cancer, potentially doubling its addressable market.

Spark’s Take on AMIX Stock

According to Spark, TipRanks’ AI Analyst, AMIX is a Neutral.

Autonomix Medical, Inc. scores low due to severe financial performance issues, characterized by zero revenue and negative cash flows, despite low debt levels. Technical analysis shows potential short-term momentum, but a longer-term downtrend persists. Valuation is the weakest, with negative earnings and no dividend yield. The lack of earnings call data means no immediate guidance to offset these challenges, resulting in a low overall score.

To see Spark’s full report on AMIX stock, click here.